Loading…
Loading…
EQUITY / NASDAQ · XNCM
60 Degrees Pharmaceuticals Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.4083 USD · 1.3165%
Observed: Oct 2, 2026, 11:52 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 1.39 USD · Volume 199,931
250 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Revenue | 207,898 USD | 100,932 USD | +105.98% |
| Operating profit | -2,271,102 USD | -1,606,328 USD | — |
| Net income | -2,264,526 USD | -1,733,726 USD | — |
| Cash and cash equivalents | 1,022,606 USD | — | — |
| Total liabilities | 1,754,271 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 1,022,606 USD | — | — | 1,510,065 USD | 1,510,065 USD | 4,115,779 USD | — | — |
| Gross profitIncome statement | 56,798 USD | 133,175 USD | — | — | 223,776 USD | -100,088 USD | 41,073 USD | 50,881 USD |
| Net incomeIncome statement | -2,264,526 USD | -4,353,740 USD | -2,090,155 USD | — | -7,365,158 USD | -2,316,324 USD | -5,926,599 USD | -1,733,726 USD |
| Operating profitIncome statement | -2,271,102 USD | -4,366,063 USD | — | — | -7,758,579 USD | -2,325,525 USD | -5,841,228 USD | -1,606,328 USD |
| RevenueIncome statement | 207,898 USD | 369,990 USD | — | — | 1,005,471 USD | 437,602 USD | 702,086 USD | 100,932 USD |
| Total assetsBalance sheet | 4,282,694 USD | — | — | 5,366,211 USD | 5,366,211 USD | 6,689,344 USD | — | — |
| Total equityBalance sheet | 2,614,185 USD | — | 4,744,479 USD | 3,463,177 USD | 3,463,177 USD | 4,430,220 USD | — | 2,345,704 USD |
| Total liabilitiesBalance sheet | 1,754,271 USD | — | — | 1,986,795 USD | 1,986,795 USD | 2,342,386 USD | — | — |
| Capital expendituresCash flow statement | — | 30,000 USD | — | — | 139,881 USD | — | 60,000 USD | — |
| Financing cash flowCash flow statement | — | 3,369,752 USD | — | — | 6,437,691 USD | — | 5,979,077 USD | — |
| Investing cash flowCash flow statement | — | 1,107,576 USD | — | — | 254,916 USD | — | 1,625,347 USD | — |
| Operating cash flowCash flow statement | — | -4,973,280 USD | — | — | -6,849,022 USD | — | -5,156,566 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 03/30/2026 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.